GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

• Status: Completed
• Trial end date: 2006-10-25
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the safety of medicine on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 56 weeks, and subjects will visit the clinic 16 times. Subjects will be given breathing tests, and will record their breathing symptoms daily on diary cards.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fluticasone; Fluticasone Propionate, Salmeterol Xinafoate Drug Combination; Salmeterol Xinafoate; Xhance

Criteria

Inclusion criteria:

• Diagnosis of COPD.

Exclusion criteria:

• Diagnosis of asthma or an uncontrolled medical condition or respiratory disorder other than COPD.

• Other inclusion and exclusion criteria will be evaluated at the first study visit.